Antitrust matters are rarely isolated within a single state or federal agency or jurisdiction. We represent clients facing multi-dimensional antitrust challenges on the transactional, regulatory and litigation fronts, mobilizing an unmatched combination of courtroom excellence, government experience and legal, economic and academic prowess on our clients’ behalf.
Paul, Weiss won a major appeal in the Fifth Circuit on behalf of client Becton, Dickinson and Company (BD) in a long-running antitrust and false advertising litigation brought by competitor Retractable Technologies, Inc. (RTI).
Awards & Recognition
Corporate partner Scott Barshay and litigation partner Rick Rule have been named American Lawyer “Dealmakers of the Year.”
Cigna announced that the Antitrust Division of the DOJ cleared Cigna’s $67 billion acquisition of pharmacy benefits manager Express Scripts Holding.
In April, the multi-venue merger litigation between the Federal Trade Commission (FTC) and paint pigment suppliers Tronox Limited and Cristal moved toward a resolution: the deal parties agreed with the FTC to divest pigment manufacturing plants in North America.
In a victory for client Nomura and other defendant banks, Paul, Weiss and other joint defense firms won the dismissal of a consolidated class action alleging that Nomura and other major global financial institutions conspired to manipulate prices in the multitrillion-dollar global market for supranational, sub-sovereign and agency (SSA) bonds.
Craig Benson, Joseph Bial, Andrew Forman, Ken Gallo, Jonathan Kanter, William Michael, Rick Rule and Aidan Synnott co-authored an article, "Takeaways From Senate Antitrust Enforcement Hearing," that appeared in the Expert Analysis section of Law360.
Paul, Weiss secured a significant antitrust appellate victory for global medical technology company Becton Dickinson & Company (BD).
As reported in The Wall Street Journal, Bloomberg, Reuters and other media outlets, Paul, Weiss client Elanco U.S., Inc., a subsidiary of Paul, Weiss client Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine and rabies vaccines portfolio, as well as a fully integrated manufacturing and R&D site, for $885 million.